The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris.
OPV
desmoglein
disease severity
oral pemphigus vulgaris
remission
rituximab
Journal
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
ISSN: 1600-0714
Titre abrégé: J Oral Pathol Med
Pays: Denmark
ID NLM: 8911934
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
28
05
2019
revised:
06
08
2019
accepted:
13
08
2019
pubmed:
20
8
2019
medline:
31
1
2020
entrez:
18
8
2019
Statut:
ppublish
Résumé
Pemphigus vulgaris patients with exclusive oral involvement (OPV) treated with conventional immunosuppressive therapy may be non-responders or experience severe side effects and/or relapses. In such cases, rituximab could be used as an adjuvant in recalcitrant OPV patients. A retrospective single-center study on patients with oral pemphigus vulgaris treated with RTX at a dose of 375 mg/m We treated 10 OPV patients, of which 60% had a moderate and 40% mild disease severity before therapy with RTX. Complete clinical remission (CCR) was achieved in 100% of OPV patients, of which 20% developed side effects and 20% experienced a relapse in a mean time of 15.2 ± 10.2 weeks. The mean time for CCR was achieved in 19.8 ± 10.3 weeks, whereas the duration of the CCR consisted in 37.4 ± 33.5 weeks. OPV patients underwent a mean follow-up of 57.2 ± 37.7 weeks. In all patients, the mean of pemphigus disease area index (PDAI) decreased from 20.3 ± 14.1 to 0.4 ± 0.0, whereas the mean Dsg3 value dropped from 157.1 ± 40.6 to 67.0 ± 26.6 after therapy with RTX. However, no correlation was found between PDAI and anti-Dsg3 antibodies before and after therapy with RTX (P > .05). RTX represents a valid and safe alternative as an adjuvant in OPV patients with low rate of relapses and side effects.
Sections du résumé
BACKGROUND
BACKGROUND
Pemphigus vulgaris patients with exclusive oral involvement (OPV) treated with conventional immunosuppressive therapy may be non-responders or experience severe side effects and/or relapses. In such cases, rituximab could be used as an adjuvant in recalcitrant OPV patients.
METHODS
METHODS
A retrospective single-center study on patients with oral pemphigus vulgaris treated with RTX at a dose of 375 mg/m
RESULTS
RESULTS
We treated 10 OPV patients, of which 60% had a moderate and 40% mild disease severity before therapy with RTX. Complete clinical remission (CCR) was achieved in 100% of OPV patients, of which 20% developed side effects and 20% experienced a relapse in a mean time of 15.2 ± 10.2 weeks. The mean time for CCR was achieved in 19.8 ± 10.3 weeks, whereas the duration of the CCR consisted in 37.4 ± 33.5 weeks. OPV patients underwent a mean follow-up of 57.2 ± 37.7 weeks. In all patients, the mean of pemphigus disease area index (PDAI) decreased from 20.3 ± 14.1 to 0.4 ± 0.0, whereas the mean Dsg3 value dropped from 157.1 ± 40.6 to 67.0 ± 26.6 after therapy with RTX. However, no correlation was found between PDAI and anti-Dsg3 antibodies before and after therapy with RTX (P > .05).
CONCLUSIONS
CONCLUSIONS
RTX represents a valid and safe alternative as an adjuvant in OPV patients with low rate of relapses and side effects.
Substances chimiques
Desmoglein 3
0
Immunosuppressive Agents
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-95Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primer. 2017;3:17026.
Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131-138.
Mignogna MD, Fortuna G, Leuci S, Ruoppo E. Oropharyngeal pemphigus vulgaris and clinical remission: a long-term, longitudinal study. Am J Clin Dermatol. 2010;11:137-145.
Rosenbach M, Murrell DF, Bystryn J-C, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol. 2009;129:2404-2410.
Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043-1046.
Iranzo P, Pigem R, Giavedoni P, Alsina-Gibert M. Remission time after rituximab treatment for autoimmune bullous disease: a proposed update definition. Skin Pharmacol Physiol. 2015;28:255-256.
Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pità O. Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67:617-622.
Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772-1779.
Abasq C, Mouquet H, Gilbert D, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol. 2009;145:529-535.
Balighi K, Sakhi R-S, Daneshpazhooh M, Mahmoudi H, Teimourpour A, Tavakolpour S. Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab. Dermatol Ther. 2018;31:e12671.
Arduino PG, Broccoletti R, Carbone M, et al. Long-term evaluation of pemphigus vulgaris: a retrospective consideration of 98 patients treated in an oral medicine unit in north-west Italy. J Oral Pathol Med. 2019;48:406-412.
Vinay K, Cazzaniga S, Amber KT, Feldmeyer L, Naldi L, Borradori L. Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long-term outcomes at a single center. J Am Acad Dermatol. 2018;78:806-808.